Postoperative Pain After Gynecological Surgery
Conditions
Interventions
A:Group A received a loading dose of 1 mg Tegilide followed by a Tegilide PCA pump, with the analgesic pump formulation consisting of 5 mg Tegilide diluted in 200 mL normal saline (0.025 mg/mL), auto-
B:Group B received a loading dose of 1 mg Tegilide followed by a Tegilide PCA pump, with the analgesic pump formulation consisting of 10 mg Tegilide diluted in 200 mL normal saline (0.05 mg/mL), auto-
C:Group C received a loading dose of 1 mg Tegilide followed by a Tegilide PCA pump, with the analgesic pump formulation consisting of 20 mg Tegilide diluted in 200 mL normal saline (0.1 mg/mL), auto-a
Sponsors
Women’s Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital
Eligibility
Sex/Gender
Female
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: Our study population consisted of patients aged 18–65 years with ASA classification I or II who were scheduled for elective gynecological surgery, including laparoscopic or open procedures, and planned to receive general anesthesia.
Exclusion criteria
Exclusion criteria: 1. Body weight 35 kg/m²; 2. Pregnancy or lactation status; 3. Severe comorbidities involving the heart, lungs, liver, or kidneys; 4. Current use of opioid or non-opioid analgesics for pain management; 5. Concurrent use of other medications that may affect pain response, such as central adrenergic agents (clonidine/dextromethorphan), antiepileptics, sedatives, antidepressants, or antipsychotics; 6. History of drug addiction or alcohol abuse; 7. Corticosteroid use within 3 months; 8. Inability to complete postoperative follow-up visits or poor compliance with visit schedules; 9. Intraoperative change of surgical approach; 10. History of intubation difficulty or anticipated difficult airway. 11. Additional postoperative exclusion criteria included anesthetic adverse events (e.g., allergic reactions, bronchospasm) and surgical complications such as vascular/neural injury, organ damage, subcutaneous emphysema, or postoperative infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sum of differences in resting pain intensity within 24 hours postoperatively (rSPID24); | — |
Secondary
| Measure | Time frame |
|---|---|
| rSPID 6;rSPID 12;rSPID 48;rSPID 12-24;rSPID 24-48;Sum of differences in activity pain intensity within 6 hours postoperatively (aSPID);aSPID 12);aSPID 24;aSPID 48;aSPID 12 -24;aSPID 24 -48;the time of first PCA administration;frequency of analgesic pump compression within 48 hours;Frequency and dosage of rescue analgesics ;opioid analgesic consumption within 48 hours;Percentage of patients with time-related unused rescue analgesics;Incidence of respiratory depression 48 hours postoperatively;Incidence of nausea and vomiting;Incidence of intestinal dysfunction (dyspepsia and first bowel movement time);Headache incidence rate;Incidence of pruritus;Ramsay Sedation Scale;Patient satisfaction with analgesia;Length of hospital stay;Preoperative and postoperative biochemical indicators related to liver and kidney function; | — |
Countries
China
Contacts
Public ContactWang Xian ; Wang Zhaohui
Women’s Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital
Outcome results
None listed